141 related articles for article (PubMed ID: 33885909)
1. Glucosamine attenuates drug resistance in Mitoxantrone-resistance breast cancer cells.
Valinezhad Sani F; Palizban A; Mosaffa F; Jamialahmadi K
J Pharm Pharmacol; 2021 Jun; 73(7):922-927. PubMed ID: 33885909
[TBL] [Abstract][Full Text] [Related]
2. Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition.
Shi RZ; He YF; Wen J; Niu YN; Gao Y; Liu LH; Zhang XP; Wang Y; Zhang XL; Zhang HF; Chen M; Hu XL
Cell Biol Int; 2021 Aug; 45(8):1644-1653. PubMed ID: 33760350
[TBL] [Abstract][Full Text] [Related]
3. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
4. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.
Wang Y; Zhao L; Xiao Q; Jiang L; He M; Bai X; Ma M; Jiao X; Wei M
Gynecol Oncol; 2016 Jun; 141(3):592-601. PubMed ID: 26644266
[TBL] [Abstract][Full Text] [Related]
5. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
7. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.
Shi R; Wang C; Fu N; Liu L; Zhu D; Wei Z; Zhang H; Xing J; Wang Y
Oncol Rep; 2019 May; 41(5):3015-3026. PubMed ID: 30896886
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.
Chen WJ; Wang H; Tang Y; Liu CL; Li HL; Li WT
Chin J Cancer; 2010 Feb; 29(2):151-7. PubMed ID: 20109342
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
Elahian F; Kalalinia F; Behravan J
Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
[TBL] [Abstract][Full Text] [Related]
11. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells.
Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508
[TBL] [Abstract][Full Text] [Related]
13. Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells.
Valinezhad Sani F; Palizban A; Mosaffa F; Jamialahmadi K
Eur J Pharmacol; 2020 Feb; 868():172883. PubMed ID: 31866406
[TBL] [Abstract][Full Text] [Related]
14. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
15. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
16. Metabolites of ginsenosides as novel BCRP inhibitors.
Jin J; Shahi S; Kang HK; van Veen HW; Fan TP
Biochem Biophys Res Commun; 2006 Jul; 345(4):1308-14. PubMed ID: 16729968
[TBL] [Abstract][Full Text] [Related]
17. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
[TBL] [Abstract][Full Text] [Related]
18. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.
Mosaffa F; Lage H; Afshari JT; Behravan J
Inflamm Res; 2009 Oct; 58(10):669-76. PubMed ID: 19333723
[TBL] [Abstract][Full Text] [Related]
20. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Kalalinia F; Elahian F; Behravan J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):321-30. PubMed ID: 20422426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
